SEC Form 4 · accession 0001209191-19-005445
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Pernock
Officer — Pres. & Chief Comm. Officer
Period of report
Jan 7, 2019
Accepted (ET)
Jan 25, 2019 · 8:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 7, 2019 | F | 858 | $41.33 | D | 10,108 | D | |
| Common StockF2,F3 | Jan 23, 2019 | A | 20,900 | — | A | 31,008 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F4 | $42.40 | Jan 23, 2019 | A | 46,600 | A | — | Jan 23, 2029 | Common Stock | 46,600 | 46,600 | D |
Explanation of responses
- F1Represents shares withheld to satisfy withholding tax obligations.
- F2Represents restricted stock units ("RSUs"). The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the one, two, three and four-year anniversaries of January 23, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
- F3Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F4The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 23, 2020, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.